At Jalon Therapeutics, we share strong understanding of the limitations of current anticancer therapies. We believe new strategies based on non-oncogene addiction could make a meaningful and durable difference for cancer patients.

Play Video

Non-Oncogene Addiction, potential target for disruptive therapies

The concept of “oncogene addiction” was created by Bernard Weinstein, describing the physiological dependency of cancer cells to continuous activation or overexpression of oncogenes (see below: IB
Weinstein, Science 2002; NAGEL R. EMBO 2016).

Many drugs targeting these oncogenes have been developed and have become highly successful therapies. Still, there are genes that are not oncogenic, not mutated nor necessarily aberrantly expressed in tumor cells but are essential for tumor cell survival through the support of oncogenic stress. In contrast, normal cells, that exhibit lower level of stress, are less dependent on these cellular pathways. This concept was framed as “non-oncogene addiction”.

” Despite the focus on oncogenes as targets of cancer therapeutics, there are solid arguments based on experimental evidence for a larger class of drug targets that are not oncogenes but if targeted could be equally effective at treating cancer” (see below: NL Solimini et al., Cell 2007).

Jalon Therapeutics aims to leverage the potential of non-oncogene addiction (NOA) to identify new therapeutic targets and develop disruptive anti-cancer treatment strategies

target the intracellular AAC-11 signaling complexes

AAC-11 protein, cornerstone of cellular stress pathways

The protein AAC-11 is not an oncogene. It is a cornerstone of the cellular stress pathways. AAC-11 is involved in cancer cells survival, growth, metastasis as well as resistance to treatments. As a scaffold protein, AAC-11 operates inside the cell with multiple partners through protein-protein interactions that promote and sustain their diseased state. This central role makes inhibition of AAC-11 functions an attractive new strategy to treat cancer. Disrupting AAC-11 functional interactions opens new avenues in cancer therapy.


JRT39, first-in-class lead candidate in advanced preclinical stage

Jalon Therapeutics’ lead candidate, JRT39, was designed to penetrate cells and specifically and efficiently target the intracellular AAC-11 signaling complexes.

JRT39 was selected for its superior preclinical efficacy in antitumor assays, preliminary stability and pharmacokinetic profiles. JRT39 is a 39 amino acid peptide comprising a sequence derived from the leucine-zipper domain of AAC-11 that specifically interacts with many of its protein partners.
This sequence is fused to a short cell-penetrating peptidic sequence that allows JRT39 to cross cell membranes.

JRT39 possesses singular features. Its optimized sequence and chemical modifications substantially prevent JRT39 cleavage by proteases. The resulting increased stability, cell-penetrating abilities and broad tissue distribution confer JRT39 unique pharmacological properties.

On a pharmacological standpoint, JRT39 has two anti-cancer modes of action:

  • By acting as a molecular decoy, it disrupts AAC-11 intracellular complexes,
    preventing AAC-11 to interact with its molecular partners. This inhibits the vital function of AAC-11 and therefore induces the spontaneous death of the cancer cells, without harming the normal (non-cancerous) cells.
  • In addition, JRT39 binds to AAC-11 partners present at the membrane level of tumor cells. Then, JRT39 specific folded shape and sequence cause the destruction of cancer cells through a membranolytic mechanism leading to highly immunogenic cell death.


Jalon Therapeutics plans to extend its scientific platform with other candidates derived from AAC-11 and AAC-11 functional partners. Our drug candidates are protected by worldwide and exclusive patents originally registered by Jean-Luc Poyet’s Inserm team and licensed to Jalon Therapeutics in 2021 and 2022.


Non-oncogene addiction

Bernard Weinstein

Addiction to Oncogenes–the Achilles Heal of Cancer.

SCIENCE, 2002: 297 (5578): 63-64
Solimini NL, Luo J, Elledge SJ.

Non-oncogene addiction and the stress phenotype of cancer cells.

Cell. 2007; 130(6):986.
Nagel R, Semenova EA, Berns A.

Drugging the addict: non-oncogene addiction as a target for cancer therapy.

EMBO Rep. 2016; 17(11):1516.


Habault J, Thonnart N, Pasquereau-Kotula E, Bagot M, Bensussan A, Villoutreix BO, Marie-Cardine A, Poyet JL.

PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4 + T Lymphocytes.

J Invest Dermatol. 2021; 141(9):2261
Habault J, Fraser C, Pasquereau-Kotula E, Born-Bony M, Marie-Cardine A, Poyet JL.

Efficient Therapeutic Delivery by a Novel Cell-Penetrating Peptide Derived from Acinus.

Cancers. 2020; 12(7):1858
Habault J, Kaci A, Pasquereau-Kotula E, Fraser C, Chomienne C, Dombret H, Braun T, Pla M, Poyet JL.

Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53.

Oncoimmunology. 2020; 9(1):1728871
Pasquereau-Kotula E, Habault J, Kroemer G, Poyet JL.

The anticancer peptide RT53 induces immunogenic cell death.

PLoS One. 2018; 6;13(8):e0201220
Jagot-Lacoussiere L, Kotula E, Villoutreix BO, Bruzzoni-Giovanelli H, Poyet JL.

A Cell-Penetrating Peptide Targeting AAC-11 Specifically Induces Cancer Cells Death.

Cancer Res. 2016; 15;76(18):5479